Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

/PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the succession...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Ivor Royston ,Mark Rothera ,Ashleigh Barreto ,Rogerj Pomerantz ,Cambridge University ,Head Of Investor Relations Corporate Communications ,Aegerion Pharmaceuticals Inc ,Prnewswire Viracta Therapeutics Inc ,Natural Sciences ,Nasdaq ,European Institute For Business Administration ,Viracta Therapeutics Inc ,Viracta Therapeutic Board ,Chief Executive ,Chief Executive Officer ,Viracta Board ,Silence Therapeutics ,Orchard Therapeutics ,Chief Commercial Officer ,Global President ,Aegerion Pharmaceuticals ,Vice President ,General Manager ,Shire Human Genetic Therapies ,Middle East ,European Institute ,Business Administration ,Viracta Therapeutics ,Private Securities Litigation Reform Act ,Relations Contact ,Investor Relations ,Nc ,